Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All budesonide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Antiviral Effect of Budesonide against SARS-CoV-2

Heinen et al., Viruses, doi:10.3390/v13071411
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Budesonide for COVID-19
19th treatment shown to reduce risk in April 2021
 
*, now with p = 0.0000011 from 15 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 95 treatments. c19early.org
In Vitro study showing dose-dependent inhibition of SARS-CoV-2 with budesonide.
3 preclinical studies support the efficacy of budesonide for COVID-19:
Heinen et al., 20 Jul 2021, peer-reviewed, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperBudesonideAll
Antiviral Effect of Budesonide against SARS-CoV-2
Natalie Heinen, Toni Luise Meister, Mara Klöhn, Eike Steinmann, Daniel Todt, Stephanie Pfaender
Viruses, doi:10.3390/v13071411
Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.
Author Contributions: S.P. designed the project; N.H. and T.L.M. performed the experiments; N.H., S.P. and M.K. wrote the manuscript; D.T. evaluated the data; E.S. and S.P. supervised the study. All authors have read and agreed to the published version of the manuscript. Funding: This research received no external funding. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: The data generated and analyzed in this study are included in the article. Viruses 2021, 13, 1411 Conflicts of Interest: The authors declare no conflict of interest.
References
Arabi, Mandourah, Al-Hameed, Sindi, Almekhlafi et al., Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome, Am. J. Respir. Crit. Care Med, doi:10.1164/rccm.201706-1172OC
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19-Final Report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Chen, Li, Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19, Clin. Infect. Dis, doi:10.1093/cid/ciaa832
Davies, Carroll, Li, Poh, Kirkegard et al., Budesonide and formoterol reduce early innate anti-viral immune responses in vitro, PLoS ONE, doi:10.1371/journal.pone.0027898
Deliloglu, Tuzun, Cengiz, Ozkan, Duman, Endotracheal Surfactant Combined With Budesonide for Neonatal ARDS, Front. Pediatr, doi:10.3389/fped.2020.00210
Ding, Feng, Chen, Yuan, Yi et al., Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study, Infect. Dis. Ther, doi:10.1007/s40121-020-00337-y
Gibson, Saltos, Fakes, Acute anti-inflammatory effects of inhaled budesonide in asthma: A randomized controlled trial, Am. J. Respir. Crit. Care Med, doi:10.1164/ajrccm.163.1.9807061
Halpin, Faner, Sibila, Badia, Agusti, Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?, Lancet Respir. Med, doi:10.1016/S2213-2600(20)30167-3
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2021436
Kelly, Busse, Jarjour, Inhaled budesonide decreases airway inflammatory response to allergen, Am. J. Respir. Crit. Care Med, doi:10.1164/ajrccm.162.3.9910077
Kim, Song, Ahn, Lee, Ahn et al., Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation, Antiviral Res, doi:10.1016/j.antiviral.2018.01.012
Li, Hu, Song, High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19, Clin. Infect. Dis, doi:10.1093/cid/ciaa829
Matsuyama, Kawase, Nao, Shirato, Ujike et al., The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells, J. Virol, doi:10.1128/JVI.01648-20
Mendes, Rebolledo, Campos, Wanner, Immediate antiinflammatory effects of inhaled budesonide in patients with asthma, Ann. Am. Thorac. Soc, doi:10.1513/AnnalsATS.201307-220OC
Mohamed, Meguid, Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study, Saudi J. Anaesth, doi:10.4103/1658-354X.197369
Ramakrishnan, Nicolau, Langford, Mahdi, Jeffers et al., Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial, Lancet Respir. Med, doi:10.1016/S2213-2600(21)00160-0
Sterne, Murthy, Diaz, Slutsky, Villar et al., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, JAMA, doi:10.1001/jama.2020.17023
Szafranski, Cukier, Ramirez, Menga, Sansores et al., Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease, Eur. Respir. J, doi:10.1183/09031936.03.00031402
Torres Acosta, Singer, Pathogenesis of COVID-19-induced ARDS: Implications for an ageing population, Eur. Respir. J, doi:10.1183/13993003.02049-2020
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Yamaya, Nishimura, Deng, Sugawara, Watanabe et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells, Respir. Investig, doi:10.1016/j.resinv.2019.12.005
Zetterström, Buhl, Mellem, Perpiñá, Hedman et al., Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone, Eur. Respir. J, doi:10.1183/09031936.01.00065801
Zhou, Dejnirattisai, Supasa, Liu, Mentzer et al., Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell
Zhu, Zhang, Wang, Li, Yang et al., A Novel Coronavirus from Patients with Pneumonia in China, N. Engl. J. Med, doi:10.1056/NEJMoa2001017
{ 'indexed': {'date-parts': [[2024, 5, 6]], 'date-time': '2024-05-06T22:35:51Z', 'timestamp': 1715034951723}, 'reference-count': 30, 'publisher': 'MDPI AG', 'issue': '7', 'license': [ { 'start': { 'date-parts': [[2021, 7, 20]], 'date-time': '2021-07-20T00:00:00Z', 'timestamp': 1626739200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Treatment options for COVID-19, a disease caused by Severe\xa0Acute\xa0Respiratory\xa0' 'Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, ' 'antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms ' 'are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of ' 'treatment for COVID-19, partly based on a previous study that reported reduced recovery times ' 'in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. ' 'Given various reports that describe the potential antiviral activity of glucocorticoids ' 'against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide ' 'against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 ' '(beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between ' 'all viral variants tested while cell viability remains unaffected. Our results are ' 'encouraging as they could indicate a multimodal mode of action of budesonide against ' 'SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.</jats:p>', 'DOI': '10.3390/v13071411', 'type': 'journal-article', 'created': {'date-parts': [[2021, 7, 20]], 'date-time': '2021-07-20T15:26:10Z', 'timestamp': 1626794770000}, 'page': '1411', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': 'Antiviral Effect of Budesonide against SARS-CoV-2', 'prefix': '10.3390', 'volume': '13', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-0906-5073', 'authenticated-orcid': False, 'given': 'Natalie', 'family': 'Heinen', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8962-9443', 'authenticated-orcid': False, 'given': 'Toni Luise', 'family': 'Meister', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7707-2040', 'authenticated-orcid': False, 'given': 'Mara', 'family': 'Klöhn', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eike', 'family': 'Steinmann', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3564-1014', 'authenticated-orcid': False, 'given': 'Daniel', 'family': 'Todt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stephanie', 'family': 'Pfaender', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'published-online': {'date-parts': [[2021, 7, 20]]}, 'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001017'}, {'key': 'ref2'}, {'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, {'key': 'ref4'}, {'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, {'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2021.02.037'}, { 'key': 'ref7', 'unstructured': 'COG-UK report on SARS-CoV-2 Spike mutations of interestin the UK\n' 'https://www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2_COG-UK_SARS-CoV-2-Mutations.pdf'}, {'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00160-0'}, {'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(20)30167-3'}, {'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/09031936.01.00065801'}, { 'key': 'ref11', 'unstructured': 'Global Strategy for Asthma Management and Prevention\n' 'https://ginasthma.org/wp-content/uploads/2021/04/GINA-2021-Main-Report_FINAL_21_04_28-WMS.pdf'}, {'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/09031936.03.00031402'}, {'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2018.01.012'}, {'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.01648-20'}, {'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.resinv.2019.12.005'}, { 'key': 'ref16', 'unstructured': 'Therapeutics and COVID-19\n' 'https://apps.who.int/iris/bitstream/handle/10665/336729/WHO-2019-nCov-remdesivir-2020.1-eng.pdf'}, {'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-020-00337-y'}, {'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa832'}, {'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/rccm.201706-1172OC'}, {'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa829'}, {'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.17023'}, {'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'}, {'key': 'ref23'}, {'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/13993003.02049-2020'}, {'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fped.2020.00210'}, {'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.4103/1658-354X.197369'}, {'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0027898'}, {'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/ajrccm.163.1.9807061'}, {'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/ajrccm.162.3.9910077'}, {'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1513/AnnalsATS.201307-220OC'}], 'container-title': 'Viruses', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/1999-4915/13/7/1411/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 7, 20]], 'date-time': '2021-07-20T17:18:23Z', 'timestamp': 1626801503000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/1999-4915/13/7/1411'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 20]]}, 'references-count': 30, 'journal-issue': {'issue': '7', 'published-online': {'date-parts': [[2021, 7]]}}, 'alternative-id': ['v13071411'], 'URL': 'http://dx.doi.org/10.3390/v13071411', 'relation': {}, 'ISSN': ['1999-4915'], 'subject': [], 'container-title-short': 'Viruses', 'published': {'date-parts': [[2021, 7, 20]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit